Table 1.
Demographic and clinical characteristics of patients and healthy controls.
| nfvPPA | svPPA | lvPPA | HC | |
|---|---|---|---|---|
| Number | 16 | 17 | 11 | 20 |
| Gender (m/f) | 8/8 | 11/6 | 4/7 | 11/9 |
| Scanning parameter | 11/5 | 12/5 | 10/1 | 14/6 |
| Age (years) | 67.50 ± 7.42 | 62.53 ± 7.77 | 65.36 ± 6.25 | 67.05 ± 6.61 |
| Education (years) | 13.19 ± 4.29 | 15.35 ± 3.37 | 13.27 ± 3.35 | 14.10 ± 3.04 |
| Disease duration (years) | 2.19 ± 1.60 | 3.59 ± 2.45 | 3.64 ± 2.66 | – |
| Total grey matter density (dm3) | 0.54 ± 0.08 | 0.52 ± 0.08 | 0.51 ± 0.09 | 0.59 ± 0.05 |
| CDR | 3.44 ± 3.20 | 5.32 ± 4.19 | 4.64 ± 4.43 | 0.03 ± 0.11 |
| FTLD-CDR | 5.94 ± 4.07 | 7.88 ± 5.44 | 6.86 ± 5.81 | 0.05 ± 0.15 |
| CERAD Plus (test battery) | ||||
| MMSE | 19.94 ± 7.25 | 19.31 ± 8.35 | 22.10 ± 6.03 | 28.70 ± 0.92 |
| Word list memory (trials 1–3) | 13.07 ± 6.61 | 13.92 ± 7.62 | 11.64 ± 8.93 | 23.40 ± 3.03 |
| Word list recall | 4.33 ± 2.62 | 3.77 ± 3.30 | 3.73 ± 3.88 | 8.20 ± 2.38 |
| Word list recognition (yes) | 8.57 ± 2.41 | 8.85 ± 1.41 | 9.10 ± 1.20 | 9.80 ± 0.52 |
| Word list recognition (no) | 9.57 ± 0.65 | 7.69 ± 2.63 | 8.40 ± 3.34 | 10.00 ± 0.00 |
| Constructional praxis | 9.06 ± 1.95 | 10.00 ± 2.08 | 8.18 ± 3.31 | 11.00 ± 0.00 |
| Constructional praxis recall | 6.75 ± 2.86 | 6.31 ± 4.31 | 4.55 ± 4.28 | 9.45 ± 1.91 |
| Trail Making Test A (s) | 94.38 ± 46.95 | 75.69 ± 51.56 | 75.80 ± 51.33 | 35.80 ± 9.01 |
| Trail Making Test B (s) | 220.18 ± 91.33 | 123.70 ± 72.24 | 201.13 ± 84.47 | 74.50 ± 19.12 |
| Boston Naming Test | 9.93 ± 4.76 | 6.47 ± 4.26 | 10.18 ± 3.89 | 14.85 ± 0.49 |
| Verbal Fluency Test | 8.06 ± 7.34 | 8.00 ± 5.01 | 12.09 ± 8.49 | 26.75 ± 5.50 |
| Phonemic Fluency Test | 3.87 ± 4.09 | 7.23 ± 5.29 | 6.80 ± 4.52 | 18.20 ± 4.63 |
| Repeat and Point Test | ||||
| Repeat task | 7.93 ± 2.34 | 8.93 ± 1.98 | 6.80 ± 3.36 | 10.00 ± 0.00 |
| Point task | 8.53 ± 1.55 | 6.14 ± 2.85 | 8.10 ± 1.91 | 9.88 ± 0.49 |
CDR clinical dementia rating scale, global score, CERAD Consortium to Establish a Registry for Alzheimer's Disease, FTLD frontotemporal lobar degeneration, HC healthy controls, lvPPA logopenic variant PPA, MMSE Mini-Mental State Examination, nfvPPA nonfluent/agrammatic variant PPA, PPA primary progressive aphasia, svPPA semantic variant PPA. Note age, education, disease duration, CDR, FTLD-CDR, CERAD Plus, and Repeat and Point Test are indicated as mean ± standard deviation. Note that data was missing for a few subjects on some subtests of the CERAD Plus and the Repeat and Point Test.